Table 2.
Characteristic | Patients using eHealth for RAa (n=134) | Patients not using eHealth (n=441) |
P value | ||
Demographic characteristics | |||||
|
Gender (female), n (%) | 110/134 (82) | 337/440 (76.5) | .18 | |
|
Age (years), mean (SD), (n=569) | 58.4 (13.2) | 62.8 (12.1) | <.001 | |
|
BMI (kg/m²), mean (SD), (n=553) | 25.2 (5.0) | 25.7 (5.1) | .32 | |
|
Living place, n (%) |
|
|
.35 | |
|
|
Urban | 60/132 (45.4) | 174/426 (40.8) |
|
|
|
Rural | 72/132 (54.5) | 252/426 (59.1) | |
|
Education level, n (%) |
|
|
.006 | |
|
|
Undergraduate or middle school | 53/126 (42) | 237/424 (55.8) |
|
|
|
High school or college | 73/126 (57.9) | 187/424 (43.3) | |
|
Employment status,
n (%)
|
|
.006 | ||
|
|
Farmer, artisan, worker | 10/132 (7.5) | 45/431 (10.4) |
|
|
|
Senior framework, employed | 49/132 (37.1) | 97/431 (22.5) | |
|
|
Unemployed | 19/132 (14.3) | 58/431 (13.4) | |
|
|
Retired | 54/132 (40.9) | 231/431 (53.5) | |
|
RA characteristics | ||||
|
|
RA duration (years), mean (SD), (n=551) | 15.2 (12.0) | 15.8 (10.0) | .56 |
|
|
RFb+, n (%) | 101/123 (82.1) | 333/421 (79.1) | .46 |
|
|
ACPAc+, n (%) | 101/123 (82.1) | 339/416 (81.4) | .88 |
|
|
Erosive, n (%) | 73/125 (58.4) | 274/423 (64.7) | .19 |
|
|
DAS28d-CRPe, mean (SD), (n=505) | 2.5 (1.2) | 2.6 (1.2) | .84 |
|
Treatments | ||||
|
|
Corticosteroids, n (%) | 32/128 (25) | 92/426 (21.5) | .42 |
|
|
csDMARDsf monotherapy (MTXg or other csDMARDs), n (%) | 44/128 (34.3) | 108/425 (25.4) | .046 |
|
|
bDMARDsh (IVi, SCj), n (%) | 75/128 (58.5) | 304/425 (71.5) | .006 |
|
|
Association of csDMARDs + bDMARDs, n (%) | 49/128 (38.2) | 199/425 (46.8) | .09 |
|
|
Comorbidity (Charlson index), mean (SD), (n=545) | 1.8 (1.5) | 2.7 (2.0) | <.001 |
|
Membership of a patient association, n (%) | 29/132 (21.9) | 22/432 (5) | <.001 | |
|
Patient education program, n (%) | 47/131 (35.8) | 88/428 (20.5) | <.001 |
aRA: rheumatoid arthritis.
bRF: rheumatoid factor.
cACPA: anticitrullinated protein antibodies.
dDAS28: Disease Activity Score-28.
eCRP: c-reactive protein.
fcsDMARDs: conventional synthetic disease-modifying antirheumatic drugs.
gMTX: methotrexate.
hbDMARDs: biologic disease-modifying antirheumatic drugs.
iIV: intravenous.
jSC: subcutaneous.